SLC5A2 and type 2 diabetes mellitus: Recent randomized controlled studies have shown that GLP-1 RAs and SGLT-2 inhibitors reduce the risks of CVD events11–14, and therefore the American Diabetes Association (ADA) recommends the use of GLP-1 RAs and SGLT-2 inhibitors as first-line treatments for patients with T2DM and established or a high risk of atherosclerotic CVD15.